国药现代(600420) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,606,778,071.34, a decrease of 16.54% compared to ¥3,123,407,807.27 in the same period last year[5] - Net profit attributable to shareholders was ¥361,413,759.19, representing a year-on-year increase of 9.10% from ¥331,257,150.18[5] - Basic and diluted earnings per share increased to ¥0.2695, up 9.11% from ¥0.2470 in the same period last year[5] - Operating profit for Q1 2025 was ¥509,056,478.60, slightly decreased from ¥524,600,367.61 in Q1 2024[18] - In Q1 2025, the net profit was approximately ¥423.54 million, a slight decrease of 0.6% compared to ¥425.86 million in Q1 2024[19] - The net profit attributable to the parent company increased to ¥361.41 million, up 9.1% from ¥331.26 million in the same period last year[19] Cash Flow and Investments - The net cash flow from operating activities decreased by 57.15%, amounting to ¥304,807,330.15, down from ¥711,404,907.55 in the previous year[5] - Cash flow from operating activities in Q1 2025 was ¥304.81 million, down 57.1% from ¥711.40 million in Q1 2024[21] - Total cash inflow from operating activities decreased to ¥2.21 billion, a decline of 29.5% from ¥3.14 billion in the previous year[21] - The company reported a net cash outflow from investing activities of approximately ¥337.87 million in Q1 2025, compared to a net outflow of ¥185.26 million in Q1 2024[22] - The company received cash of ¥1.06 billion related to investment activities in Q1 2025, indicating a significant increase in cash inflow from investments[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥19,328,793,560.17, a decrease of 3.14% from ¥19,955,597,470.69 at the end of the previous year[5] - Total liabilities decreased to ¥3,583,289,440.24 as of March 31, 2025, from ¥4,633,633,097.68 at the end of 2024[15] - Cash and cash equivalents were ¥5,109,086,433.09 as of March 31, 2025, down from ¥6,211,941,467.03 at the end of 2024[13] - Inventory as of March 31, 2025, was ¥2,091,351,135.35, a decrease from ¥2,208,799,259.06 at the end of 2024[13] - Non-current assets totaled ¥8,400,755,287.40 as of March 31, 2025, an increase from ¥8,271,493,346.47 at the end of 2024[14] Shareholder Information - The company had a total of 40,821 common shareholders at the end of the reporting period[10] - The largest shareholder, Shanghai Pharmaceutical Industry Research Institute Co., Ltd., held 239,512,622 shares, accounting for 17.86% of total shares[11] - The company did not report any significant changes in shareholder participation in financing or securities lending activities during the period[12] Other Financial Metrics - The weighted average return on net assets increased to 2.70%, up by 0.06 percentage points from 2.64%[5] - Non-recurring gains and losses totaled ¥15,146,012.94 for the period, with significant contributions from government subsidies and fair value changes of financial assets[7] - The company reported an investment income of ¥20,681,510.13 in Q1 2025, significantly higher than ¥2,479,299.44 in Q1 2024[18] - The impact of exchange rate changes on cash and cash equivalents was a positive ¥12.18 million in Q1 2025, compared to ¥2.50 million in Q1 2024[22]